GlassScriptPhysician profile
Christopher Medina
NPI 1639707169
$5,270.39
in general payments reported to CMS, 2019-2025
13 companies · $4,995 in 2025
The $4,995 reported for 2025 was more than what 85% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $276 · 2025: $4,995.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,669 · Food and Beverage: $1,602.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,668.56 |
| Food and Beverage | $1,601.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $3,909.17 | 2025 | Iovera |
| Amgen INC. | $368.08 | 2025 | Otezla, Repatha |
| Madrigal Pharmaceuticals | $246.93 | 2024-2025 | Rezdiffra |
| Lilly USA, LLC | $204.98 | 2025 | Kisunla, Mounjaro, Zepbound |
| Teva Pharmaceuticals USA, INC. | $136.61 | 2024 | Austedo Xr, Uzedy |
| Axsome Therapeutics, INC. | $117.88 | 2025 | Symbravo |
| Bayer Healthcare Pharmaceuticals INC. | $105.41 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.02 | 2025 | Xifaxan |
| Pfizer INC. | $32.79 | 2025 | |
| Averitas Pharma INC. | $31.12 | 2025 | Qutenza |
| Bioventus LLC | $26.51 | 2025 | Durolane |
| Ardelyx, INC. | $21.77 | 2025 | Ibsrela |
| Dynavax Technologies Corporation | $16.12 | 2025 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Medina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.